August 4, 2021 - August 6, 2021

Windlas Biotech IPO Review & Recommendations

InvestorGain.com has given "Apply" recommendation to Windlas Biotech IPO. Dilip Davda has given "May Apply" recommendation to Windlas Biotech IPO. JM Financial Institutional Securities has "Neutral" view about the IPO. Capital Market recommend to "Avoid" the IPO.

Windlas Biotech IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	1	1	1	1	0
%	25.00	25.00	25.00	25.00	0.00

Windlas Biotech IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Capital Market	Avoid
Dilip Davda	May Apply
JM Financial Institutional Securities	Neutral
InvestorGain.com	Apply

Windlas Biotech IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Windlas Biotech IPO is 39. Their analysis recommends Do not subscribe for the IPO.

Reviewer	Rating Score	Rating
Capital Market	39	Do not subscribe

Windlas Biotech IPO Review by Dilip Davda (May apply)

[Dilip Davda] Despite growth in its top lines, WBL has posted declining trends for bottom lines in order to clear its slate. Based on its financial parameters, the issue is aggressively priced. All recent moves will take about two years to be on a fast forward mode. Thus it is purely a long term bet at the current valuations that discounts all near term positives. Cash surplus investors may consider it with a long term perspective. Read detail review...

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.